Synta Pharmaceuticals Announces Ganetespib Results at American Association for Cancer Research – Inhibition of Multiple Oncogenes and Resistance Mechanisms Leads to Potent Activity in NSCLC and Strong Enhancement of Radiation Therapy

LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today presented five posters at the American Association for Cancer Research (AACR) 102nd Annual Meeting. Three posters reported results from studies of ganetespib (STA-9090), and two posters reported results from studies of elesclomol, a small-molecule mitochondria metabolism inhibitor.